Last reviewed · How we verify
Universidad Autonoma de Nuevo Leon — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
2 Phase 3
2 Phase 2
2 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Betamethason Sodium Phosphate | Betamethason Sodium Phosphate | marketed | ||||
| Acetaminophen 500mg | Acetaminophen 500mg | marketed | ||||
| Botulinum Toxins, Type A | Botulinum Toxins, Type A | phase 3 | Neurotoxin; Acetylcholine release inhibitor | SNAP-25 (synaptosome-associated protein of 25 kDa) | Neurology; Dermatology; Aesthetics | |
| Doxophylline | Doxophylline | phase 3 | Other |
Therapeutic area mix
- Neurology; Dermatology; Aesthetics · 1
- Other · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Croma-Pharma GmbH · 1 shared drug class
- EvergreenHealth · 1 shared drug class
- Helse Nord-Trøndelag HF · 1 shared drug class
- NICHD Pelvic Floor Disorders Network · 1 shared drug class
- University of Calgary · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Universidad Autonoma de Nuevo Leon:
- Universidad Autonoma de Nuevo Leon pipeline updates — RSS
- Universidad Autonoma de Nuevo Leon pipeline updates — Atom
- Universidad Autonoma de Nuevo Leon pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Universidad Autonoma de Nuevo Leon — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universidad-autonoma-de-nuevo-leon. Accessed 2026-05-17.